WallStSmart
PRME

Prime Medicine, Inc. Common Stock

NASDAQ: PRME · HEALTHCARE · BIOTECHNOLOGY

$3.53
-4.34% today

Updated 2026-04-29

Market cap
$666.47M
P/E ratio
P/S ratio
143.88x
EPS (TTM)
$-1.35
Dividend yield
52W range
$1 – $7
Volume
2.5M

Prime Medicine, Inc. Common Stock (PRME) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
8 of 8
Last 8 quarters
Avg EPS surprise
+11.6%
Last 4 quarters
Revenue YoY growth
-61.6%
Most recent quarter
EPS YoY growth
+22.6%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-13.6%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-15.7%
2025-11-07
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-03$-0.24+6.9%$4.66$4.12-11.6%
2025-11-07$-0.32+25.6%$4.18$3.53-15.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.26$-0.24+6.9%$838000.00-61.6%
2025-09-30$-0.43$-0.32+25.6%$1.23M+486.1%
2025-06-30$-0.43$-0.41+4.7%$1.11M-97.0%
2025-03-31$-0.44$-0.40+9.1%$1.45M+146.0%
2024-12-31$-0.49$-0.31+36.7%$2.18M-91.5%
2024-09-30$-0.49$-0.44+10.2%$209000.00
2024-06-30$-0.49$-0.46+6.1%$37.77M
2024-03-31$-0.47$-0.44+6.4%$591000.00
2023-12-31$-0.51$-0.72-41.2%$25.69M
2023-09-30$-0.46$-0.55-19.6%
2023-06-30$-0.42$-0.47-11.9%
2023-03-31$-0.41$-0.44-7.3%

Frequently asked questions

Has Prime Medicine, Inc. Common Stock beaten earnings estimates?
Prime Medicine, Inc. Common Stock has beaten Wall Street EPS estimates in 8 of its last 8 quarterly reports, with an average EPS surprise of +11.6% over the last 4 quarters.
How does PRME stock react to earnings?
PRME stock has moved an average of -13.6% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Prime Medicine, Inc. Common Stock's revenue growth rate?
Prime Medicine, Inc. Common Stock reported year-over-year revenue growth of -61.6% in its most recent quarter, with EPS growing +22.6% year-over-year.